Frecuencia de eventos trombóticos y sangrado en pacientes usuarios de la clínica anticoagulación del Hospital Militar Central 2019-2020

Largo Gil, Jorge Mario

dc.contributor.advisor	Largo Gil, Jorge Mario
dc.contributor.author	Largo Gil, Jorge Mario
dc.contributor.other	Palomino Ariza, Gustavo Alejandro
dc.coverage.spatial	Hospital militar central	spa
dc.coverage.spatial	Bogotá	spa
dc.coverage.temporal	2019- 2020	spa
dc.date.accessioned	2022-02-08T16:53:26Z
dc.date.available	2022-02-08T16:53:26Z
dc.date.issued	2022-01-31
dc.identifier.uri	http://hdl.handle.net/10654/39989
dc.description.abstract	Los anticoagulantes son un grupo farmacológico, con amplio uso alrededor del mundo para la prevención y tratamiento de las enfermedades trombóticas. Las clínicas de anticoagulación son un equipo de atención integral del paciente usuario de anticoagulantes, que entre algunas de sus funciones está el de estandarizar el tratamiento, seguimiento, educación y vigilancia de los pacientes para impactar en desenlaces como prevención de complicaciones asociadas.	spa
dc.description.tableofcontents	1. RESUMEN 7 2. MARCO TEÓRICO 11 2.1. HEMOSTASIA 13 2.2. EVENTOS TROMBÓTICOS RELEVANTES EN LA CLÍNICA 21 2.2.1. Fibrilación auricular 21 2.2.2. Enfermedad tromboembólica venosa 22 2.2.3. Prótesis valvulares cardiacas mecánicas 24 2.3. ESTRATEGIAS ANTICOAGULANTES 25 2.3.1. Anticoagulantes antagonistas de la Vitamina K 25 2.3.2. Anticoagulantes directos no dependientes de Vitamina K 29 2.3.3. Heparinas de bajo peso molecular 29 2.4. COMPLICACIONES DE LA TERAPIA ANTICOAGULANTE 36 2.4.1. Sangrado 36 3. IDENTIFICACIÓN Y FORMULACIÓN DEL PROBLEMA 39 3.1. PREGUNTA DE INVESTIGACIÓN 42 4. JUSTIFICACIÓN 43 5. OBJETIVOS E HIPÓTESIS 47 5.1. OBJETIVO PRINCIPAL 47 5.2. OBJETIVOS SECUNDARIOS 47 6. METODOLOGÍA 48 6.1. TIPO Y DISEÑO GENERAL 48 6.2. LUGAR DONDE SE REALIZARÁ LA INVESTIGACIÓN 48 6.3. POBLACION 48 6.4. SELECCIÓN Y TAMAÑO DE MUESTRA 48 6.5. CRITERIOS DE INCLUSIÓN Y EXCLUSIÓN 48 6.6. DEFINICIÓN DE LAS VARIABLES 48 6.7. ESTRATEGIAS PARA SUPRIMIR AMENAZAS A LA VALIDEZ DE RESULTADOS 63 6.8. MEDICIONES E INSTRUMENTOS 63 7. PLAN DE ANÁLISIS 65 8. ASPECTOS ÉTICOS 65 9. RESULTADOS 67 10. DISCUSION 69 11.ANEXOS 74 12. CONCLUSIONES 78 13.REFERENCIAS BIBLIOGRÁFICAS 83	spa
dc.format.mimetype	applicaction/pdf	spa
dc.language.iso	spa	spa
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.title	Frecuencia de eventos trombóticos y sangrado en pacientes usuarios de la clínica anticoagulación del Hospital Militar Central 2019-2020	spa
dc.rights.accessrights	info:eu-repo/semantics/openAccess	spa
dc.type.local	Tesis/Trabajo de grado - Monografía - Especialización	spa
dc.description.abstractenglish	Anticoagulants are a pharmacological group, widely used around the world for the prevention and treatment of thrombotic diseases. The anticoagulation clinics are a comprehensive care team for patients who use anticoagulants, which among some of its functions is to standardize the treatment, follow-up, education and surveillance of patients to impact outcomes such as prevention of associated complications.	spa
dc.title.translated	Frequency of thrombotic events and bleeding in patients using the anticoagulation clinic of the Hospital Militar Central -2019-2020 Autores	spa
dc.subject.keywords	warfarin	spa
dc.subject.keywords	direct anticoagulants	spa
dc.subject.keywords	bleeding	spa
dc.subject.keywords	thromboembolism	spa
dc.subject.keywords	anticoagulation clinic	spa
dc.publisher.program	Medicina Interna	spa
dc.creator.degreename	Especialista en Medicina Interna	spa
dc.subject.decs	TROMBOSIS	spa
dc.subject.decs	MEDICINA INTERNA	spa
dc.subject.decs	ANTICOAGULANTES	spa
dc.subject.decs	EMBOLIA	spa
dc.description.degreelevel	Especialización	spa
dc.publisher.faculty	Facultad de Medicina	spa
dc.type.driver	info:eu-repo/semantics/bachelorThesis	spa
dc.rights.creativecommons	Attribution-NonCommercial-NoDerivatives 4.0 International	spa
dc.relation.references	1. Nutescu EA. The future of anticoagulation clinics. J Thrombosis and Thrombolysis 2003; 16 (1/2): 61-63	spa
dc.relation.references	2. Anseel JE, Hughes RM. Involving models of warfarin management: anticoagulation clinics, patient selfmonitoring and patients self-management. Am Heart J 1996; 1095-1100	spa
dc.relation.references	3. Chiquette E, Amanto MG, Bussey HI. Comparison of an anticoagulation clinics with usual medical care anticoagulation control, patient outcomes and health care cost. Arch Intern Med 1998; 158: 1641-1647	spa
dc.relation.references	4. Gadisseur AP, Kaptein AA, Breukink-Engbers WG, van der Meer FJ, Rosendaal FR. Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life. J Thromb Haemost 2004; 2 (4): 584-91	spa
dc.relation.references	5. Cromheecke ME, Colly LP, et al. Oral anticoagulation selfmanagement and management by a specialist anticoagulation clinics: a randomized cross-over comparison. Lancet 2000; 353 (8).	spa
dc.relation.references	6. Macik BG. The future of anticoagulation clinics. J Thrombosis and Thrombolysis 2003; 16 (1/2): 55-59.	spa
dc.relation.references	7. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Sixth ACCP. Consensus Conference on Antithrombotic Therapy. Chest 2001; 119 (1) (suppl): 8S- 21S	spa
dc.relation.references	8. Hernandez DA, Palomino GA, Caracterizacion de la clinica de anticoagulacion del hospital militar central. Recuperado el 10 de agosto de 2021, URL :http://hdl.handle.net/10654/34920. Universidad Militar Nueva Granada	spa
dc.relation.references	9. Franchini M, Mannucci PM. New anticoagulants for treatment of venous thromboembolism. Eur J Intern Med. 2012;23(8):692---5	spa
dc.relation.references	10. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, GolitsynS, et al. Apixaban in patients with auricular auricular fibrillation.N Engl J Med. 2011;364(9):806---17.	spa
dc.relation.references	11. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM,Hanna M, et al. Apixaban versus warfarin in patients wit-hauricular auricular fibrillation. N Engl J Med. 2011;365(11):981---92.5.	spa
dc.relation.references	12. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P; European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625–651	spa
dc.relation.references	13. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467–1507.	spa
dc.relation.references	14. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek	spa
dc.relation.references	15. B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–2962.	spa
dc.relation.references	16. Sáenz M O, Sanabria F, Rubio AM, González A F, Gamba N. Clínica de anticoagulación de la Subred Centro Oriente, en Bogotá. rev. colomb. neumol. [Internet]. 6 de julio de 2021 [citado 20 de enero de 2022];32(2):37-45. Disponible en: https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/531	spa
dc.relation.references	17. J. Steffel et al. 2018 EHRA Practical Guide on NOACs in AF. European Heart Journal (2018) 39, 1330–1393	spa
dc.relation.references	18. Ocampo C, Hernández O, Velásquez C, Tobón I, Mejía F. La clínica de anticoagulación del Hospital Universitario San Vicentede Paúl: demografía, efectividad y complicaciones. Iatreia.2004;17(2):105---14.	spa
dc.relation.references	19. Taboada LB, Silva LE, Montenegro AC. Beneficios de la clínica de anticoagulación. Acta Med Colomb. 2013;38:239---43	spa
dc.relation.references	20. Ligia P. Laverde, Sonia E. Gómez, Ana C. Montenegro, Alberto Lineros, Beatriz Wills y Andrés F. Buitrago. Experiencia de una clínica de anticoagulación. Rev Colomb Cardiol. 2015;22(5):224---230	spa
dc.relation.references	21. Corey S. Miller, BA, Sonia M Grandi, MSc, Avi Shimony, MD, Kristian B Filion, PhD, and Mark J. Eisenberg, MD, MPH. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versis Warfarin in Patients With Atrial Fibrillation. Am J Cardiol 2012;110:453-460)	spa
dc.relation.references	22. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, et al. Oral anticoagulant therapy: Antithrombo-tic Therapy and Prevention of Thrombosis, 9th. ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141 2 Suppl:e44S---88S.	spa
dc.relation.references	23. Bruce Furie, M.D., and Barbara C. Furie, Ph.D. Mechanisms of Thrombus Formation. New England Journal of Medicine 2008;359:938-49.	spa
dc.relation.references	24. Kojima H, Newton-Nash D, Weiss HJ, et al. Production and characterization of transformed B-lymphocytes expressing the membrane defect of Scott syndrome. J Clin Invest 1994; 94:2237.	spa
dc.relation.references	25. Hansson K, Stenflo J. Post-translational modifications in proteins involved in blood coagulation. J Thromb Haemost 2005; 3:2633.	spa
dc.relation.references	26. Mann KG, Brummel-Ziedins K, Orfeo T, Butenas S. Models of blood coagulation. Blood Cells Mol Dis 2006; 36:108.	spa
dc.relation.references	27. Morrison SA, Jesty J. Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood 1984; 63:1338.	spa
dc.relation.references	28. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns Hj. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; Feb 137(2):263 - 72	spa
dc.relation.references	29. Ntauis G, et al. CHADS2, CHA2DS2-VASc, and long term stroke outcome in patientes without atrial fibrillation. Neurology, March 12; 80(11): 1009-17	spa
dc.relation.references	30. Ostranderld JR, Brandt RL, Kjelsberg M, Eppstein FH. Electrocardiographic findings among the adult population of a total natural community, Te cumshed, Michigan. Circulation 1965; 31: 888-98.	spa
dc.relation.references	31. Kannel W, Abbott RD, Savage AD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham study. N Eng J Med 1982; 306: 1018-22.	spa
dc.relation.references	32. Vidaillet H, Granada JF, Chyou et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 2002; 113: 365-70.	spa
dc.relation.references	33. Wolf P, D’Agostino R, Belanger A et al. Probality of stroke: a risk profile from the Framingham study. Stroke 1991; 22: 312-8.	spa
dc.relation.references	34. Wolf P, Dawber T, Thomas H et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28: 973-7.	spa
dc.relation.references	35. Stöllberger C, Chnupa P, Kronik G et al. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. Ann Intern Med 1998; 128: 630-8.	spa
dc.relation.references	36. Chimowitz M, DeGeorgia M, Poole R et al. Left atrial spontaneous echo contrast is highly associated with previous stroke in patients with atrial fibrillation or mitral stenosis. Stroke 1993; 24: 1015-9.	spa
dc.relation.references	37. Heppell RM, Berkin K, McLenachan et al. Haemostatic and haemodinamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart 1997; 77: 407-11.	spa
dc.relation.references	38. Friberg L, Rosenquist M, Lip GY. Evaluation of risk stratificationschemes for ischaemic stroke and bleeding in 182678 patientes with atrial fibrillation: the Swedish Atrial Fibrillation cohort Study. Eur Heart . 2012 Jun 33(12): 1500-10.	spa
dc.relation.references	39. Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis-current understanding from an epidemiologic point of view. Br J Haematol. 2010; 149(6): 824.	spa
dc.relation.references	40. Dickson BC. Venous thrombosis: on the history of Virchow´s triad. Univ Toronto Med J. 2004; 81:166.	spa
dc.relation.references	41. Bauer KA, The thrombophilias: Well-defined risk factors with uncertain thrapeutic implications, vol. 135, p. 367. Annals of Internal Medicine. 2001	spa
dc.relation.references	42. den Exter PL, van Es J, Erkens PM, van Roosmalen MJ, et al. Impact of delay in clinical presentation on the diagnostic managment and prognosis of patientts with suspected pulmnary embolism. Am J Respir Crit Care Med. 2013 Jun; 187(12):1369-73	spa
dc.relation.references	43. Browse NL, homas ML. Source of non-lethal pulmonary emboli. Lancet. 1974; 1(7851):258.	spa
dc.relation.references	44. Nishimura RAm Otto CM, Bonow RO, Carabello BA, et al. 2014 AHA/ACC guideline for the management of patientes with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(22): e57. Epub 2014 Mar 3	spa
dc.relation.references	45. Hirsh J, Weitz JI. New antithrombotic agents. Lancet. 1999;353(9162):1431.	spa
dc.relation.references	46. Laux V, Perzborn E, Heitmeier S, von Degenfeld G, Dittrich-Wengenroth E, Buchmüller A, Gerdes C, Misselwitz F. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?. Thromb Haemost. 2009;102(5):892.	spa
dc.relation.references	47. Samama MM. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants. Thromb Res. 2011 Jun;127(6):497-504. Epub 2010 Oct 2.	spa
dc.relation.references	48. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRADAXA Capsules safely and effectively . Disponible en: https://docs.boehringeringelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf	spa
dc.relation.references	49. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116. Epub 2010 Mar 29.	spa
dc.relation.references	50. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49(4):259.	spa
dc.relation.references	51. Gosselin RC, Adcock DM, Bates SM, et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost 2018; 118:437.	spa
dc.relation.references	52. Douros A, Azoulay L, Yin H, et al. Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury. J Am Coll Cardiol 2018; 71:1105.1.37).	spa
dc.relation.references	53. Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14:1308.	spa
dc.relation.references	54. Moore KT, Kröll D. Influences of Obesity and Bariatric Surgery on the Clinical and Pharmacologic Profile of Rivaroxaban. Am J Med 2017; 130:1024.	spa
dc.relation.references	55. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022406s004lbl.pdf	spa
dc.relation.references	56. Beyer-Westendorf J, Siegert G. Of men and meals. J Thromb Haemost 2015; 13:943.	spa
dc.relation.references	57. Poulsen BK, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 2012; 72:1739.	spa
dc.relation.references	58. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011; 31:326.	spa
dc.relation.references	59. http://packageinserts.bms.com/pi/pi_eliquis.pdf	spa
dc.relation.references	60. Stergiopoulos K, Brown DL. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med 2014; 174:1330.	spa
dc.relation.references	61. Belley-Cote EP, Hanif H, D'Aragon F, et al. Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis. Thromb Haemost 2015; 114:768.	spa
dc.relation.references	62. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126:133	spa
dc.relation.references	63. Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999; 159:46.	spa
dc.relation.references	64. Farahmand S, Saeedi M, Seyed Javadi HH, Khashayar P. High doses of warfarin are more beneficial than its low doses in patients with deep vein thrombosis. Am J Emerg Med 2011; 29:1222.	spa
dc.relation.references	65. Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med 2003; 138:714.	spa
dc.relation.references	66. Cushman M, Booth SL, Possidente CJ, et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112:572.	spa
dc.relation.references	67. Lubetsky A, Dekel-Stern E, Chetrit A, et al. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost 1999; 81:396.	spa
dc.relation.references	68. Khan T, Wynne H, Wood P, et al. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol 2004; 124:348.	spa
dc.relation.references	69. Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med 2004; 116:651.	spa
dc.relation.references	70. Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009; 20:912.	spa
dc.relation.references	71. Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol 2011; 154:311.	spa
dc.relation.references	72. Garcia P, Ruiz W, Loza Munárriz C. Warfarin initiation nomograms for venous thromboembolism. Cochrane Database Syst Rev 2016; :CD007699.	spa
dc.relation.references	73. Poller L, Keown M, Ibrahim S, et al. An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost 2008; 6:935.	spa
dc.relation.references	74. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84:326.	spa
dc.relation.references	75. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e152S.	spa
dc.relation.references	76. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S.	spa
dc.relation.references	77. Barnes GD, Froehlich JB. Anticoagulation: a pathway to clinical effectiveness. Am J Med 2009; 122:126	spa
dc.relation.references	78. Kim YK, Nieuwlaat R, Connolly SJ, et al. Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. J Thromb Haemost 2010; 8:101	spa
dc.relation.references	79. Le Gal G, Carrier M, Tierney S, et al. Prediction of the warfarin maintenance dose after completion of the 10 mg initiation nomogram: do we really need genotyping? J Thromb Haemost 2010; 8:90.	spa
dc.relation.references	80. Borgman MP, Pendleton RC, McMillin GA, et al. Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation. Thromb Haemost 2012; 108:561.	spa
dc.relation.references	81. Van Spall HG, Wallentin L, Yusuf S, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 2012; 126:2309.	spa
dc.relation.references	82. Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91:472.	spa
dc.relation.references	83. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376:975	spa
dc.relation.references	84. Rose AJ, Ozonoff A, Berlowitz DR, et al. Warfarin dose management affects INR control. J Thromb Haemost 2009; 7:94.	spa
dc.relation.references	85. Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2018; 2:3257.	spa
dc.relation.references	86. Metlay JP, Hennessy S, Localio AR, et al. Patient reported receipt of medication instructions for warfarin is associated with reduced risk of serious bleeding events. J Gen Intern Med 2008; 23:1589.	spa
dc.relation.references	87. Kaatz S. Determinants and measures of quality in oral anticoagulation therapy. J Thromb Thrombolysis 2008; 25:61.	spa
dc.relation.references	88. Phillips KW, Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and suring high-quality management. Expert Rev Cardiovasc Ther 2008; 6:57.	spa
dc.relation.references	89. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129:1155.	spa
dc.relation.references	90. Muñoz EM, Linhardt RJ. Heparin-binding domains in vascular biology. Arterioscler Thromb Vasc Biol 2004; 24:1549.	spa
dc.relation.references	91. Masuko S, Linhardt RJ. Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics. Future Med Chem 2012; 4:289.	spa
dc.relation.references	92. Grigas D, Hodous T, Welton W, Pearson D. Medical grand rounds from the West Virginia University Hospital. Sarcoidosis. W V Med J 1978; 74:242.	spa
dc.relation.references	93. Ceri H, Hwang WS, Cheung H. Endogenous heparin-binding lectin activity in human placenta: purification and developmental expression. Biochem Cell Biol 1990; 68:790.	spa
dc.relation.references	94. Tessler S, Rockwell P, Hicklin D, et al. Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. J Biol Chem 1994; 269:12456.	spa
dc.relation.references	95. Fatma N, Singh DP, Shinohara T, Chylack LT Jr. Heparin's roles in stabilizing, potentiating, and transporting LEDGF into the nucleus. Invest Ophthalmol Vis Sci 2000; 41:2648.	spa
dc.relation.references	96. Wijelath E, Namekata M, Murray J, et al. Multiple mechanisms for exogenous heparin modulation of vascular endothelial growth factor activity. J Cell Biochem 2010; 111:461.	spa
dc.relation.references	97. Baglin T, Barrowcliffe TW, Cohen A, et al. Guidelines on the use and monitoring of heparin. Br J Haematol 2006; 133:19.	spa
dc.relation.references	98. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:141S	spa
dc.relation.references	99. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688.	spa
dc.relation.references	100. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79:1.	spa
dc.relation.references	101. Prandoni P. Heparins and venous thromboembolism: current practice and future directions. Thromb Haemost 2001; 86:488.	spa
dc.relation.references	102. White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same? Br J Haematol 2003; 121:12.	spa
dc.relation.references	103. Choay J, Petitou M, Lormeau JC, et al. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116:492.	spa
dc.relation.references	104. Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev 1994; 8:37.	spa
dc.relation.references	105. Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest 1984; 74:341.	spa
dc.relation.references	106. Danielsson A, Raub E, Lindahl U, Björk I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986; 261:15467.	spa
dc.relation.references	107. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020164s083lbl.pdf.	spa
dc.relation.references	108. Rojas L, Aizman A, Ernst D, et al. Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms. Thromb Res 2013; 132:761.	spa
dc.relation.references	109. Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e24S.	spa
dc.relation.references	110. W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144:673.	spa
dc.relation.references	111. Crowther M, Lim W. Low molecular weight heparin and bleeding in patients with chronic renal failure. Curr Opin Pulm Med 2007; 13:409.	spa
dc.relation.references	112. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 2002; 162:2605.	spa
dc.relation.references	113. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124:2450.	spa
dc.relation.references	114. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383:955.	spa
dc.relation.references	115. Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010; 104:1099	spa
dc.relation.references	116. Jiang R, Shi Y, Zhang R, et al. Comparative efficacy and safety of low-intensity warfarin therapy in preventing unprovoked recurrent venous thromboembolism: A systematic review and meta-analysis. Clin Respir J 2018; 12:2170.	spa
dc.relation.references	117. Robert-Ebadi H, Le Gal G, Righini M. Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging 2009; 4:165.	spa
dc.relation.references	118. Benedetti G, Neccia M, Agati L. Direct oral anticoagulants use in elderly patients with non valvular atrial fibrillation: state of evidence. Minerva Cardioangiol 2018; 66:301.	spa
dc.relation.references	119. Huhtakangas J, Tetri S, Juvela S, et al. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke 2011; 42:2431	spa
dc.relation.references	120. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10:417.	spa
dc.relation.references	121. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138:1093.	spa
dc.relation.references	122. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57:173.	spa
dc.relation.references	123. Olesen JB, Lip GY, Hansen PR, et al. Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost 2011; 9:1460.	spa
dc.relation.references	124. Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012; 60:861	spa
dc.relation.references	125. Cairns JA, Connolly S, McMurtry S, et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011; 27:74.	spa
dc.relation.references	126. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37:2893.	spa
dc.relation.references	127. Asunción Esteve-Pastor M, Miguel Rivera-Caravaca J, Roldán V, et al. Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. Thromb Haemost 2017; 117:1848.	spa
dc.relation.references	128. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58:395.	spa
dc.relation.references	129. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105:91.	spa
dc.relation.references	130. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151:713.	spa
dc.relation.references	131. Pengo V, Pegoraro C, Cucchini U, Iliceto S. Worldwide ma-nagement of oral anticoagulant therapy: the ISAM study.J Thromb Thrombolysis. 2006;21(1):73-7. doi: 10.1007/s11239-006-5580-y	spa
dc.subject.proposal	Warfarina	spa
dc.subject.proposal	Anticoagulantes directos	spa
dc.subject.proposal	Clinica anticoagulacion	spa
dc.subject.proposal	tromboembolismo	spa
dc.subject.proposal	sangrado	spa
dc.publisher.grantor	Universidad Militar Nueva Granada	spa
dc.type.coar	http://purl.org/coar/resource_type/c_7a1f	*
dc.type.hasversion	info:eu-repo/semantics/acceptedVersion	spa
dc.identifier.instname	instname:Universidad Militar Nueva Granada	spa
dc.identifier.reponame	reponame:Repositorio Institucional Universidad Militar Nueva Granada	spa
dc.identifier.repourl	repourl:https://repository.unimilitar.edu.co	spa
dc.rights.local	Acceso abierto	spa
dc.coverage.sede	Medicina	spa
dc.rights.coar	http://purl.org/coar/access_right/c_abf2